GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

GSK's Q4 sales hit $10.40 billion, topping estimates. Specialty Medicines grew 14%, while vaccines declined. The company ...

GSK has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly surpassing market expectations. The fourth quarter contributed £8.1 billion, a 4% rise ...

A scientist working in Switzerland has become the fifth person to be convicted of attempting to steal trade secrets from pharmaceutical ... attempted to re-brand GSK products under development ...

A doctor and a patient discussing a therapy plan that includes pharmaceutical products. Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a British global pharmaceutical and healthcare ...

The annual per capita pharmaceutical sales are less than US$32. Most of this spent is out of the pocket. By providing a big portfolio of 140 products with a relative low price, GSK is winning the ...

The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

The British pharma giant plans to shell out ... despite existing approved products,” Luke Miels, chief commercial officer at GSK, said in Monday’s announcement. Just last August, IDRx raised ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...